Battery-Powered Skin Patch for PAD treatment

Scientists have confirmed the feasibility of using a new drug delivery system - the basis for a battery-powered skin patch - to administer medication that shows promise for treating peripheral artery disease (PAD) and healing stubborn skin ulcers and burns. The needle-free delivery of the medication, which cannot be given by mouth and can have side effects when injected, is reported in the ACS journal, Molecular Pharmaceutics.

Yogeshvar Kalia and colleagues explain that the medication consists of fibroblast growth factors (FGFs), proteins that have shown promise for treating skin conditions and PAD, which causes pain in the legs, buttocks, and feet due to blocked arteries in the legs. However, FGFs become inactive if given by mouth, and their injection can result in kidney and eye damage. The scientists had previously shown that a drug delivery technology called transdermal iontophoresis can deliver medicines made from small proteins. But would the technique, which involves encouraging medicine through the skin with a small electric current, work for larger proteins like FGFs?

Their laboratory tests with samples of human skin and pig skin showed that iontophoresis did work - in contrast, no FGF was delivered without electricity. Four times more medication remained in the skin than passed through which was also an advantage. Most importantly, the medicine remained biologically active in the skin. The results confirm the feasibility of using iontophoresis to deliver medicines consisting of larger proteins, including FGFs, the scientists note.

 

11.08.2011

More on the subject:

Related articles

Photo

News • Preclinical study

Lung cancer: new approach to reduce radiation-related damage

Radiotherapy can be lifesaving for patients with lung cancer, but may also damage healthy lung tissue and limit future treatments. Discovery of a new immune pathway could help prevent this damage.

Photo

News • Molecular imaging

HER2-positive breast cancer: PET/CT technique shows promise for predicting treatment response

Molecular imaging with ⁶⁸Ga-HER2 PET/CT may provide an early, targeted measure of how well treatment is working in patients with HER2-positive breast cancer, according to new research.

Photo

News • Trial investigates combined benefits

Liquid biopsy and mammography: a perfect match for breast cancer detection?

Could a liquid biopsy blood test help detect breast cancer earlier than a mammogram alone? A new clinical trial to evaluate this question has just started.

Subscribe to Newsletter